Ardelyx

Yahoo Finance • 10 months ago

Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call Transcript

Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call Transcript February 22, 2024 Ardelyx, Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.09. Ardelyx, Inc. isn’t one of the 30 most popular stocks amon... Full story

Yahoo Finance • last year

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • last year

Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • last year

XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia

WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • last year

Ardelyx Announces Departure of Board Member

WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • last year

Ardelyx to Participate at the Jefferies London Healthcare Conference

WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • last year

Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States

XPHOZAH is the first and only FDA approved phosphate absorption inhibitor Best-in-class patient services programs support patient access and affordability for XPHOZAH patients WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx,... Full story

Yahoo Finance • last year

Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023

WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Ardelyx, Inc., Leslie’s, Inc., Enovix Corporation, and Fate Therapeutics, Inc. If you a... Full story

Yahoo Finance • last year

Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023

WALTHAM, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • last year

Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023

WALTHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • last year

Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital

WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • last year

FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor

XPHOZAH has been approved to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate... Full story

Yahoo Finance • last year

Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA

WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • last year

Market Today: Pfizer's Acquisition of Seagen Under Review, NextEra Energy Rebounds, and Tempest ...

The S&P 500, Dow Jones Industrial Average, and Nasdaq Composite all saw gains on 10-11-2023, with the S&P 500 advancing by 0.43%, the Dow Jones finishing 0.19% higher, and the Nasdaq Composite rising by 0.71%. The 10-year Treasury yield fe... Full story

Yahoo Finance • last year

Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023

WALTHAM, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • last year

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet m... Full story

Yahoo Finance • last year

Tenapanor for Hyperphosphatemia Approved in Japan

Approval announced by Kyowa Kirin, Ardelyx Collaboration Partner Ardelyx to receive $30 million from Kyowa Kirin in milestone and license amendment payments and $5 million from HealthCare Royalty Partners under a Financing Agreement WALT... Full story

Yahoo Finance • last year

Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference

WALTHAM, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet m... Full story

Yahoo Finance • last year

Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

WALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story